PTC's plans crash into regulatory reality as FDA demands data on 2 candidates,...

[cafead]

via PTC Therapeutics is keeping its regulatory teams busy. In its third-quarter results, the biotech reported pushback against its plans to seek approval for two molecules based on existing data—and saw its share price fall more than 20% in the wake of the update.

article source